Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022; quarter-end cash and restricted cash position was $497.0 millionPhase 3 VITAL study data on observed survival benefit in Mayo Stage IV AL amyloidosis patients treated with.
Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022; quarter-end cash and restricted cash position was
Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022; quarter-end cash and restricted cash position was. | November 3, 2022